Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, Doherty M, Geenen R, Hammond A, Kjeken I, Lohmander LS, Lund H, Mallen CD, Nava T, Oliver S, Pavelka K, Pitsillidou I, da Silva JA, de la Torre J, Zanoli G, Vliet Vlieland TP (2013) European League Against R EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
Semaglutide Has an FDA Indication for MASH Wegovy received FDA accelerated approval for MASH (metabolic dysfunction-associated steatohepatitis) in August 2025
The cost of peptide therapy varies widely depending on the specific compound, source, and whether insurance coverage applies
Consequently, the development of therapeutic agents that disrupt various aspects of Gln metabolism may represent a promising anticancer strategy ( Figure 2 )
The National Resource Center on Nutrition & Aging